Cell Reports · 2022 · 15 citations · 57 references
Life SciencesEndocrinologyMolecular BiologyGene ExpressionSignal TransductionTranscriptional RegulationDiabetes MellitusGlucose HomeostasisGlycemic ControlIncretin-based TherapiesPancreatic EndocrinologyPancreatic HormonesBeta Cell BiologyBeta-cell DysfunctionGlucagon-like Peptide 1 SignalingGlucagon-like PeptidesIncretin EffectIncretin HormonesPancreatic Islet BiologyPancreatic Islet Cells
The glucagon-like peptide 1 (Glp-1) has emerged as a hormone with broad pharmacological potential in type 2 diabetes (T2D) treatment, notably by improving β cell functions. The cell-cycle regulator and transcription factor E2f1 is involved in glucose homeostasis by modulating β cell mass and function. Here, we report that β cell-specific genetic ablation of E2f1 ( E2f1 β−/− ) impairs glucose homeostasis associated with decreased expression of the Glp-1 receptor ( Glp1r ) in E2f1 β−/− pancreatic islets. Pharmacological inhibition of E2F1 transcriptional activity in nondiabetic human islets decreases GLP1R levels and blunts the incretin effect of GLP1R agonist exendin-4 (ex-4) on insulin secretion. Overexpressing E2f1 in pancreatic β cells increases Glp1r expression associated with enhanced insulin secretion mediated by ex-4. Interestingly, ex-4 induces retinoblastoma protein (pRb) phosphorylation and E2f1 transcriptional activity. Our findings reveal critical roles for E2f1 in β cell function and suggest molecular crosstalk between the E2F1/pRb and GLP1R signaling pathways.
57
NIH Image to ImageJ: 25 years of image analysis
Caroline A Schneider, Wayne Rasband, Kevin W. Eliceiri · Nature Methods · 2012 · 65.2K citations
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN
Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Jens J. Holst, Cathrine Ørskov, O. Vagn Nielsen et al. · FEBS Letters · 1987 · 610 citations · Full text